Results from a multicenter registry of heparin-bonded expanded polytetrafluoroethylene graft for above-the-knee femoropopliteal bypass
Piffaretti et al. 20181
Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium
Primary patency of GORE® PROPATEN® Vascular Graft
![N=360](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-1.gif.webp?itok=iHE1pgAV)
![1 year 82%](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-2.gif.webp?itok=cdRh8sQ0)
![2 years 77.5%](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-3.gif.webp?itok=uNu10Qy1)
![3 years 74%](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-4.gif.webp?itok=Lk7Le2Gi)
![4 years 71%](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-5.gif.webp?itok=57DFXpDO)
![5 years 64%](/sites/default/files/styles/max_750x750/public/2019-06/propaten-references-6.gif.webp?itok=cTzAYTgf)
Patient characteristics
Characteristic | N | % |
---|---|---|
Rutherford classification | ||
3 | 200 | 55% |
4 | 86 | 24% |
5 | 68 | 18% |
6 | 10 | 3% |
Hypertension | 294 | 81% |
Diabetes | 141 | 39% |
History of smoking | 216 | 59% |
Study details
-
Retrospective, non-randomized, multi-center analysis
-
At the time of publication, the PROPATEN Italian registry had tracked 1,401 interventions performed for peripheral arterial obstructive disease using GORE® PROPATEN® Vascular Graft in a “real-world” setting
-
Estimated survival at 5 years was 75.3%
-
Estimated amputation-free survival at 5 years was 74%
-
Estimated assisted primary patency, secondary patency, and limb salvage at 5 years were 65%, 74.5%, and 95%, respectively
-
Postoperative medical treatment with warfarin alone was found to be an independent risk factor for loss of primary patency compared to dual antiplatelet therapy
[Above-the-knee femoropopliteal bypass] with the use of HB-ePTFE remains an effective option, with low rate of perioperative complications and satisfactory long-term results. — G. Piffaretti
…in our opinion, [Above-the-knee femoropopliteal bypass] is a valid and viable first-line alternative to endovascular surgery in long or complex lesions of the SFA. — G. Piffaretti
1. Piffaretti G, Dorigo W, Castelli P, Pratesi C, Pulli R. PROPATEN Italian Registry Group. Results from a multicenter registry of heparinbonded expanded polytetrafluoroethylene graft for above-the-knee femoropopliteal bypass. Journal of Vascular Surgery 2018;67(5):1463-1471.e1.